Abstract 1378P
Background
The management of non-small cell lung cancer (NSCLC) has transformed over the past decade through the development of immunotherapy and targeted therapies. Our objective was to evaluate the gains in survival in stage IV NSCLC by sociodemographic groups in the United States.
Methods
Patients diagnosed with and treated for Stage IV NSCLC between 2010 and 2020 in the National Cancer Database were studied in 3 eras (2010 - 2013, 2014 - 2017, and 2018 - 2020). Unadjusted survival was assessed by Kaplan Meier and stratified cox analysis was performed to evaluate differences in survival by race and ethnicity.
Results
Overall, 374,273 patients were identified. The median survival was highest across all 3 eras for Asians (12.9, 17.0, and 22.5 months) and the lowest for American Indians/Alaskan Natives (6.9, 6.9, and 9.0 months) (Table). Survival increased for all racial/ethnicity groups across eras, consistent with the development of novel therapeutics, but with considerable differences in the proportionality of gains. For example, between era 1 and 3, Hispanics experienced an 81% increase in median survival, while American Indians/Alaskan Natives experienced a 30% increase (Table). Multivariable Cox models also demonstrated considerable variability in mortality risk over time, favoring groups other than non-Hispanic white patients with the exception of American Indians/Alaskan Natives.
Table: 1378P
| 2010-2013 | 2014-2017 | 2018-2020 | |||||
| Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | % Difference in median survivalEra 3 &1 | |
| Asian | 12.8 | 0.69 (ConclusionsThere has been a dramatic improvement in survival among stage IV NSCLC over the past decade across all race and ethnicity. The rates of improvement in survival were observed to differ across sociodemographic groups, with the Hispanic patients experiencing the highest benefit. Further studies to understand variability in survival gains by type of therapy or by mutation status are warranted to understand the long-term potential disparities in cancer-related mortality. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyD. Boffa. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest. Resources from the same session1763P - Initial tumour size and residual mitotic count post-neoadjuvant imatinib linked to shorter relapse-free survival in GIST patientsPresenter: Javier Pozas Perez Session: Poster session 06 1764P - Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trialPresenter: Lennart Schardt Session: Poster session 06 1765P - Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world studyPresenter: Xinhua Zhang Session: Poster session 06 1766P - Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumorsPresenter: Bernd Kasper Session: Poster session 06 1767P - Pegylated liposomal doxorubicin in symptomatic desmoid tumorPresenter: Kjetil Boye Session: Poster session 06 1768P - Desmoid tumors: Experience of a Spanish reference centerPresenter: Ana Gutierrez Ortiz Session: Poster session 06 1769P - Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II studyPresenter: Cesar Serrano Session: Poster session 06 1771P - Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)Presenter: Sant Chawla Session: Poster session 06 1772P - Phosphoproteomic biomarker for afatinib response stratification in advanced chordomaPresenter: Christoph Stange Session: Poster session 06 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||||